Aitchison, K. J., Jann, M. W., Zhao, J. H.
et al (2000) Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice. Journal of Psychopharmacology, 14, 353–359.
Barnes, T. R. E., McEvedy, C. J. B. & Nelson, H. E. (1996) Management of treatment resistant schizophrenia unresponsive to clozapine. British Journal of Psychiatry, 169 (suppl. 31), 31–40.
Bondolfi, G., Dufour, H., Patris, M.
et al (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. American Journal of Psychiatry, 155, 499–504.
Brambilla, P., Barale, F. & Caverzasi, E. (2002) Clozapine-treated subjects with treatment-resistant schizophrenia: a systematic review of experimental and observational studies. International Journal of Clinical Psychopharmacology, 17, 189–195.
Brooks, J. O. III (2001) Successful outcome using quetiapine in a case of treatment resistant schizophrenia with assaultive behaviour. Schizophrenia Research, 50, 133–134.
Conley, R. R., Tamminga, C. A., Bartko, J. J.
et al (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry, 155, 914–920.
Conley, R. R., Tamminga, C. A., Kelly, D. L.
et al (1999) Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry, 46, 73–77.
Connolly, M. & Kelly, C. (2005) Lifestyle and physical health of people with schizophrenia. Advances in Psychiatric Treatment, 11, 125–132.
Dursun, S. M. & Deakin, J. F. (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Journal of Psychopharmacology, 15, 297–301.
Dursun, S. M., Gardner, D. M., Bird, D. C.
et al (1999) Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Canadian Journal of Psychiatry, 44, 701–704.
Fabre, L. F., Arvanitis, J., Pultz, V. M.
et al (1995) ICI 204–636 a novel atypical antipsychotic: early indications of safety and efficacy in patients with chronic and subchronic schizophrenia. Clinical Therapeutics, 17, 366–378.
Gopal, Y. V. & Variend, H. (2005) First-episode schizophrenia: review of cognitive deficits and cognitive remediation. Advances in Psychiatric Treatment, 11, 38–44.
Iqbal, M. M., Rahman, A., Husain, Z.
et al (2003) Clozapine: a clinical review of adverse effects and management. Annals of Clinical Psychiatry, 15, 33–48.
Juarez-Reyes, M. G., Shumway, M., Battle, C.
et al (1995) Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatric Services, 46, 801–806.
Kane, J. M. (1992) Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. British Journal of Psychiatry, 160 (suppl. 17), 41–45.
Kane, J. M. (1996) Factors which make patients difficult to treat. British Journal of Psychiatry, 169 (suppl. 31), 10–14.
Kane, J., Honigfeld, G., Singer, J.
et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.
Kerwin, R. W. (2000) From pharmacological profiles to clinical outcomes. International Journal of Clinical Psychopharmacology, 15, S1–S4.
Kerwin, R. W. & Osborne, S. (2000) Antipsychotic drugs. Medicine, 28, 23–25.
Leask, S. J. (2004) Environmental influences in schizophrenia: the known and the unknown. Advances in Psychiatric Treatment, 10, 323–330.
Lerner, V., Libov, I., Kotler, M.
et al (2004) Combination of ‘atypical’ antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Progress in Neuropsychopharmacology and Biological Psychiatry, 28, 89–98.
Lindenmayer, J. P., Czobor, P. & Volavka, J. (2002) Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. Journal of Clinical Psychiatry, 63, 931–935.
Ma, J. D., Nafziger, A. N. & Bertino, J. S. Jr. (2004) Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. Journal of Clinical Pharmacology, 44, 447–456.
McCreadie, R. G. (2004) Editorial: Schizophrenia revisited. Advances in Psychiatric Treatment, 10, 321–322.
Meltzer, H. Y. (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophrenia Bulletin, 18, 515–542.
Morrison, D. P. (1996) Management of treatment refractory schizophrenia. British Journal of Psychiatry, 169 (suppl. 31), 15–20.
Munro, J., Matthiasson, P., Osborne, S.
et al (2004) Amisulpride augmentation of clozapine: an open nonrandomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatrica Scandinavica, 110, 292–298.
National Institute for Clinical Excellence (2002) Clinical Guideline 1. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NICE.
Pantelis, C. & Lambert, T. J. (2003) Managing patients with ‘treatment-resistant’ schizophrenia. Medical Journal of Australia, 178 (suppl.), S62–S66.
Perry, P. J., Miller, D., Arndt, S. V.
et al (1991) Clozapine concentrations and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. American Journal of Psychiatry, 148, 231–235.
Potkin, S. G., Bera, R., Gulaskeram, B.
et al (1994) Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry, 55 (suppl. B.), 133–136.
Rowlands, P. (2004) The NICE schizophrenia guidelines: the challenge of implementation. Advances in Psychiatric Treatment, 10, 403–412.
Shiloh, R., Zemishlany, Z., Aizenberg, D.
et al (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry, 171, 569–573.
Singh, S. P. & Fisher, H. L. (2005) Early intervention in psychosis: obstacles and opportunities. Advances in Psychiatric Treatment, 11, 71–78.
Tiihonen, J., Hallikainen, T., Ryynanen, O. P.
et al (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry, 54, 1241–1248.
Tsapakis, E., Basu, A. & Aitchison, K. J. (2004) Clinical relevance of discoveries in psychopharmacogenetics. Advances in Psychiatric Treatment, 10, 455–465.
Wahlbeck, K., Cheine, M., Essali, A.
et al (1999) Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry, 156, 990–999.
Wahlbeck, K., Cheine, M. & Tuisku, K. (2000) Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry, 24, 911–922.
Zink, M., Knopf, U., Henn, F. A.
et al (2004) Combination of clozapine and amisulpride in treatment-resistant schizophrenia: case reports and review of the literature. Pharmacopsychiatry, 37, 26–31.